Market Overview
The global renal disease market is expected to grow at a CAGR of 8.2%% during the forecast period (2022-2029). The rising prevalence of chronic kidney diseases and the growing number of patients with end-stage renal disease are the major factors driving the growth of this market.
In addition, the increasing awareness about the early detection and treatment of renal diseases, the availability of advanced treatments, and the growing number of clinical trials are also contributing to the growth of this market. However, the high cost of treatment and lack of awareness in developing countries are restraining the growth of this market.
The global renal disease market is segmented by type, cause, diagnosis, and treatment. By type, the market is classified into acute kidney injury (AKI), chronic kidney disease (CKD), end-stage renal disease (ESRD), and polycystic kidney disease (PKD). By cause, the market is categorized into diabetes mellitus, hypertension, glomerulonephritis, urinary tract infection, nephrotic syndrome, and others.
By diagnosis, the market is divided into blood tests, urine tests, imaging tests, biopsies, and others. By treatment, the market is classified into dialysis (hemodialysis and peritoneal dialysis), transplantation (kidney transplantation and living donor transplantation), medications (diuretics, ACE inhibitors/ARBs/calcium channel blockers/antihypertensives
Renal disease is a debilitating and often fatal condition that affects millions of people worldwide. According to the World Health Organization, renal disease is the ninth leading cause of death globally, and its incidence is rising. There is no cure for renal disease, but early diagnosis and treatment can improve patient outcomes and slow the progression of the disease. With the aging population and the rise in chronic diseases such as diabetes and hypertension, the global renal disease market is expected to grow significantly over the next decade.
Renal diseases are disorders of the kidney caused by genetic problems, diabetes, and high blood pressure. The most common type of renal disease is chronic kidney disease (CKD), which progresses slowly over time and may lead to complete kidney failure.
The market has been segmented on the basis of disease type, treatment type, and geography. By disease type, CKD holds the largest share of the market due to its increasing prevalence across the globe. By treatment type, dialysis is the most widely used treatment for renal diseases, followed by transplantation. Geographically, North America dominates the global renal disease market due to the rising incidence of kidney diseases and the availability of advanced treatments in this region.
The major players operating in the global renal disease market are Fresenius Medical Care AG & Co., DaVita Healthcare Partners Inc., Baxter International Inc., B Braun Melsungen AG, and Diaverum Deutschland GmbH.
Market Drivers and Trends
There is a growing awareness of renal diseases and their impact on patient health and quality of life. This has led to a greater demand for treatments that can improve outcomes and reduce the burden of disease. The prevalence of renal diseases is also increasing due to the aging population and the rise in risk factors such as obesity, diabetes, and hypertension. The main drivers of market growth include the increasing prevalence of renal diseases, the launch of new therapies, and the growing awareness of kidney transplantation.
The main trends in the market include the rising use of telemedicine, the increasing use of artificial intelligence (AI) in diagnosis and treatment, and the growing number of home dialysis programs.
Report Includes
An overview of the global Renal Disease market, and related technologies and developments. Analyses of global market trends, with historical data from 2018, 2019, and 2020 estimates and projections of CAGRs through 2029. It also includes breakdowns of the overall Renal Disease market along with various segments, and by geographic region. Analysis of the stakeholder value chain in the Renal Disease market and comprehensive profiles of leading companies in the industry
Report Scope
The report forecasts the size of the Renal Disease market for components from 2022 through 2029
The Executive Summary provides a snapshot of the key findings of the report. The introduction chapter includes the research scope, market segmentation, research methodology, and definitions and assumptions. It involves extremely rigorous scientific methods, tools, and techniques to estimate the market size. Exhaustive secondary research is being carried out to collect information related to the market, the parent market, and the peer market. Primary research is undertaken to validate the assumptions, findings, and sizing with industry experts and professionals across the value chain of the market. Both top-down and bottom-up approaches are employed to estimate the complete market size.
The chapter on market dynamics includes market drivers, restraints, and opportunities which helps familiarise with market potential and upcoming opportunities. The chapter on key insights includes emerging trends from major countries, the latest technological advancement, regulatory landscape, SWOT analysis, and Porter's five forces analysis. This chapter provides detailed insights into the market, which derives the market trends, changing phase of investments, and scope of profit potential, and helps to take appropriate business decisions. The chapter on competitive analysis includes the profiling of leading companies in the global market to map the leading companies and their focus of interest in the market.
After deriving the market size from the market size estimation process, the total market has been split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures are being used. The data triangulation is carried out by studying various factors and trends from demand and supply perspectives.
Segmentation Analysis:
The global renal disease market is classified on the basis of product type, disease type, and geography.
Global Renal Disease Market Competitive Analysis:
Key players in the Global Renal Disease market are Abbott (US), Amgen Inc. (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co. KGaA (UK), GlaxoSmithKline PLC (UK), Keryx Biopharmaceuticals, Inc (US), Kissei Pharmaceutical Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France), and Teva Pharmaceutical Industries Ltd (Israel) among other players.
*All our reports are customizable as per customer requirements
This study forecasts revenue and volume growth at global, regional, and country levels from 2018 to 2029. The global Renal Disease market is distributed on the basis of the below-mentioned segments:
Global Renal Disease market, By Type:
The global renal disease market is expected to grow at a CAGR of 8.2%% during the forecast period (2022-2029). The rising prevalence of chronic kidney diseases and the growing number of patients with end-stage renal disease are the major factors driving the growth of this market.
In addition, the increasing awareness about the early detection and treatment of renal diseases, the availability of advanced treatments, and the growing number of clinical trials are also contributing to the growth of this market. However, the high cost of treatment and lack of awareness in developing countries are restraining the growth of this market.
The global renal disease market is segmented by type, cause, diagnosis, and treatment. By type, the market is classified into acute kidney injury (AKI), chronic kidney disease (CKD), end-stage renal disease (ESRD), and polycystic kidney disease (PKD). By cause, the market is categorized into diabetes mellitus, hypertension, glomerulonephritis, urinary tract infection, nephrotic syndrome, and others.
By diagnosis, the market is divided into blood tests, urine tests, imaging tests, biopsies, and others. By treatment, the market is classified into dialysis (hemodialysis and peritoneal dialysis), transplantation (kidney transplantation and living donor transplantation), medications (diuretics, ACE inhibitors/ARBs/calcium channel blockers/antihypertensives
Renal disease is a debilitating and often fatal condition that affects millions of people worldwide. According to the World Health Organization, renal disease is the ninth leading cause of death globally, and its incidence is rising. There is no cure for renal disease, but early diagnosis and treatment can improve patient outcomes and slow the progression of the disease. With the aging population and the rise in chronic diseases such as diabetes and hypertension, the global renal disease market is expected to grow significantly over the next decade.
Renal diseases are disorders of the kidney caused by genetic problems, diabetes, and high blood pressure. The most common type of renal disease is chronic kidney disease (CKD), which progresses slowly over time and may lead to complete kidney failure.
The market has been segmented on the basis of disease type, treatment type, and geography. By disease type, CKD holds the largest share of the market due to its increasing prevalence across the globe. By treatment type, dialysis is the most widely used treatment for renal diseases, followed by transplantation. Geographically, North America dominates the global renal disease market due to the rising incidence of kidney diseases and the availability of advanced treatments in this region.
The major players operating in the global renal disease market are Fresenius Medical Care AG & Co., DaVita Healthcare Partners Inc., Baxter International Inc., B Braun Melsungen AG, and Diaverum Deutschland GmbH.
Market Drivers and Trends
There is a growing awareness of renal diseases and their impact on patient health and quality of life. This has led to a greater demand for treatments that can improve outcomes and reduce the burden of disease. The prevalence of renal diseases is also increasing due to the aging population and the rise in risk factors such as obesity, diabetes, and hypertension. The main drivers of market growth include the increasing prevalence of renal diseases, the launch of new therapies, and the growing awareness of kidney transplantation.
The main trends in the market include the rising use of telemedicine, the increasing use of artificial intelligence (AI) in diagnosis and treatment, and the growing number of home dialysis programs.
Report Includes
An overview of the global Renal Disease market, and related technologies and developments. Analyses of global market trends, with historical data from 2018, 2019, and 2020 estimates and projections of CAGRs through 2029. It also includes breakdowns of the overall Renal Disease market along with various segments, and by geographic region. Analysis of the stakeholder value chain in the Renal Disease market and comprehensive profiles of leading companies in the industry
Report Scope
The report forecasts the size of the Renal Disease market for components from 2022 through 2029
The Executive Summary provides a snapshot of the key findings of the report. The introduction chapter includes the research scope, market segmentation, research methodology, and definitions and assumptions. It involves extremely rigorous scientific methods, tools, and techniques to estimate the market size. Exhaustive secondary research is being carried out to collect information related to the market, the parent market, and the peer market. Primary research is undertaken to validate the assumptions, findings, and sizing with industry experts and professionals across the value chain of the market. Both top-down and bottom-up approaches are employed to estimate the complete market size.
The chapter on market dynamics includes market drivers, restraints, and opportunities which helps familiarise with market potential and upcoming opportunities. The chapter on key insights includes emerging trends from major countries, the latest technological advancement, regulatory landscape, SWOT analysis, and Porter's five forces analysis. This chapter provides detailed insights into the market, which derives the market trends, changing phase of investments, and scope of profit potential, and helps to take appropriate business decisions. The chapter on competitive analysis includes the profiling of leading companies in the global market to map the leading companies and their focus of interest in the market.
After deriving the market size from the market size estimation process, the total market has been split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures are being used. The data triangulation is carried out by studying various factors and trends from demand and supply perspectives.
Segmentation Analysis:
The global renal disease market is classified on the basis of product type, disease type, and geography.
Global Renal Disease Market Competitive Analysis:
Key players in the Global Renal Disease market are Abbott (US), Amgen Inc. (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co. KGaA (UK), GlaxoSmithKline PLC (UK), Keryx Biopharmaceuticals, Inc (US), Kissei Pharmaceutical Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France), and Teva Pharmaceutical Industries Ltd (Israel) among other players.
*All our reports are customizable as per customer requirements
This study forecasts revenue and volume growth at global, regional, and country levels from 2018 to 2029. The global Renal Disease market is distributed on the basis of the below-mentioned segments:
Global Renal Disease market, By Type:
- Acute Kidney Problems
- Chronic Kidney Diseases
- Others
- Hospital
- Clinic
- Research Center
- Others
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Renal Disease MARKET STUDY GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2020-2027
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Segment 1
- 5.2.1. Sub-Segment 1
- 5.2.2. Sub-Segment 2
- 5.3. Market Analysis, Insights and Forecast – By Segment 2
- 5.3.1. Sub-Segment 1
- 5.3.2. Sub-Segment 2
- 5.3.3. Sub-Segment 3
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Segment 3
- 5.4.1. Sub-Segment 1
- 5.4.2. Sub-Segment 2
- 5.4.3. Sub-Segment 3
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Latin America
- 5.5.3. Europe
- 5.5.4. Asia Pacific
- 5.5.5. Middle East and Africa
6. North America Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Segment 1
- 6.2.1. Sub-Segment 1
- 6.2.2. Sub-Segment 2
- 6.3. Market Analysis, Insights and Forecast – By Segment 2
- 6.3.1. Sub-Segment 1
- 6.3.2. Sub-Segment 2
- 6.3.3. Sub-Segment 3
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast – By Segment 3
- 6.4.1. Sub-Segment 1
- 6.4.2. Sub-Segment 2
- 6.4.3. Sub-Segment 3
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Latin America Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Segment 1
- 7.2.1. Sub-Segment 1
- 7.2.2. Sub-Segment 2
- 7.3. Market Analysis, Insights and Forecast – By Segment 2
- 7.3.1. Sub-Segment 1
- 7.3.2. Sub-Segment 2
- 7.3.3. Sub-Segment 3
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast – By Segment 3
- 7.4.1. Sub-Segment 1
- 7.4.2. Sub-Segment 2
- 7.4.3. Sub-Segment 3
- 7.4.4. Others
- 7.5. Insights and Forecast – By Country
- 7.5.1. Brazil
- 7.5.2. Mexico
- 7.5.3. Rest of Latin America
8. Europe Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Segment 1
- 8.2.1. Sub-Segment 1
- 8.2.2. Sub-Segment 2
- 8.3. Market Analysis, Insights and Forecast – By Segment 2
- 8.3.1. Sub-Segment 1
- 8.3.2. Sub-Segment 2
- 8.3.3. Sub-Segment 3
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast – By Segment 3
- 8.4.1. Sub-Segment 1
- 8.4.2. Sub-Segment 2
- 8.4.3. Sub-Segment 3
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. UK
- 8.5.2. Germany
- 8.5.3. France
- 8.5.4. Italy
- 8.5.5. Spain
- 8.5.6. Russia
- 8.5.7. Rest of Europe
9. Asia Pacific Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Segment 1
- 9.2.1. Sub-Segment 1
- 9.2.2. Sub-Segment 2
- 9.3. Market Analysis, Insights and Forecast – By Segment 2
- 9.3.1. Sub-Segment 1
- 9.3.2. Sub-Segment 2
- 9.3.3. Sub-Segment 3
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast – By Segment 3
- 9.4.1. Sub-Segment 1
- 9.4.2. Sub-Segment 2
- 9.4.3. Sub-Segment 3
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. China
- 9.5.2. India
- 9.5.3. Japan
- 9.5.4. Australia
- 9.5.5. South East Asia
- 9.5.6. Rest of Asia Pacific
10. Middle East & Africa Renal Disease Market Analysis (USD Billion), Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Segment 1
- 10.2.1. Sub-Segment 1
- 10.2.2. Sub-Segment 2
- 10.3. Market Analysis, Insights and Forecast – By Segment 2
- 10.3.1. Sub-Segment 1
- 10.3.2. Sub-Segment 2
- 10.3.3. Sub-Segment 3
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast – By Segment 3
- 10.4.1. Sub-Segment 1
- 10.4.2. Sub-Segment 2
- 10.4.3. Sub-Segment 3
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast – By Country
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Company Market Share Analysis, 2018
- 11.2. Key Industry Developments
- 11.3. Company Profile
- 11.3.1. Company 1
- 11.3.1.1. Business Overview
- 11.3.1.2. Segment 1 & Service Offering
- 11.3.1.3. Overall Revenue
- 11.3.1.4. Geographic Presence
- 11.3.1.5. Recent Development
- 11.3.2. Company 2
- 11.3.3. Company 3
- 11.3.4. Company 4
- 11.3.5. Company 5
- 11.3.6. Company 6
- 11.3.7. Company 7
- 11.3.8. Company 8
- 11.3.9. Company 9
- 11.3.10. Company 10
- 11.3.11. Company 11
- 11.3.12. Company 12
- 11.3.1. Company 1
Research Process
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
